A new levodopa product (ODM-101) developed by Orion Corporation could improve the treatment of advanced Parkinson’s disease patients. According to a Phase II study, presented yesterday at American Academy of Neurology’s Annual Meeting in San Diego, ODM-101 significantly decreased daily OFF-time without increasing ON-time with troublesome dyskinesias compared to reference product Stalevo®, which is an established standard medication for advanced Parkinson’s patients experiencing so-called end-of-dose wearing off symptoms associated with levodopa therapy.
Stalevo, also a product of Orion’s own pharmaceutical R&D, contains three active substances in one tablet: levodopa and the enzyme inhibitors entacapone and carbidopa. ODM-101 has the same components as Stalevo but with higher and fixed amount of carbidopa (either 65 or 105 mg) regardless of levodopa dosage.
Read on at MedicalNewsToday.com